Skip to main content
Premium Trial:

Request an Annual Quote

Roche Extends Tender Offer for Illumina

NEW YORK (GenomeWeb News) – Roche today announced it has extended its tender offer to acquire all outstanding shares of Illumina.

The offer is now set to expire March 23 at 6 p.m. EST. It had been scheduled to expire at the end of the day Feb. 24.

Roche made its $5.7 billion hostile bid for Illumina last month with an offer of $44.50 per share. As of the end of the day Feb. 24, about 102,165 shares of Illumina had been tendered and not withdrawn pursuant to the offer, including 44,152 shares guaranteed to be delivered within the next three Nasdaq trading days, Roche said.

Last week, Roche said it would be extending its antitrust waiting period in connection to its Illumina bid.

The extension of the tender offer was expected and the whole process will likely take several months to play out. Illumina rejected the $5.7 billion offer earlier this month.

In a statement today, Illumina called the number of its shares tendered to Roche "extremely low … consistent with our view and that of our stockholders that Roche's offer does not reflect Illumina's unique leadership position business performance, and future prospects."

It added that the company "remains focused on continuing to develop breakthrough products that expand existing markets and create new ones. The potential of our industry is enormous, with major new markets emerging in medical diagnostics, reproductive health, and cancer management."

In late-morning trading on the Nasdaq, shares of Illumina were down a fraction of 1 percent at $51.01.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.